423 related articles for article (PubMed ID: 16338282)
21. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers.
Zimmermann T; Schlenk R; Pfaff G; Lach P; Wildfeuer A
Arzneimittelforschung; 1995 Jan; 45(1):41-3. PubMed ID: 7893267
[TBL] [Abstract][Full Text] [Related]
22. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
[TBL] [Abstract][Full Text] [Related]
24. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
26. [Distinguishing CYP2D6 homozygous and heterozygous extensive metabolizers by dextromethorphan phenotyping].
Chen SQ; Cai WM; Wedlund PJ
Yao Xue Xue Bao; 1997 Dec; 32(12):924-7. PubMed ID: 11596190
[TBL] [Abstract][Full Text] [Related]
27. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
28. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
29. Low-dose ritonavir moderately enhances nelfinavir exposure.
Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
[TBL] [Abstract][Full Text] [Related]
30. Metabolic activity of dextromethorphan O-demethylation in healthy Japanese volunteers carrying duplicated CYP2D6 genes: duplicated allele of CYP2D6*10 does not increase CYP2D6 metabolic activity.
Ishiguro A; Kubota T; Ishikawa H; Iga T
Clin Chim Acta; 2004 Jun; 344(1-2):201-4. PubMed ID: 15149890
[TBL] [Abstract][Full Text] [Related]
31. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
[TBL] [Abstract][Full Text] [Related]
32. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic interaction between ritonavir and clarithromycin.
Ouellet D; Hsu A; Granneman GR; Carlson G; Cavanaugh J; Guenther H; Leonard JM
Clin Pharmacol Ther; 1998 Oct; 64(4):355-62. PubMed ID: 9797791
[TBL] [Abstract][Full Text] [Related]
34. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
35. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
[TBL] [Abstract][Full Text] [Related]
36. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Avenoso A; Facciolà G; Scordo MG; Spina E
Ther Drug Monit; 1999 Oct; 21(5):577-9. PubMed ID: 10519458
[TBL] [Abstract][Full Text] [Related]
37. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
Shulman RW; Ozdemir V
Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
[TBL] [Abstract][Full Text] [Related]
38. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
39. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.
Nakashima D; Takama H; Ogasawara Y; Kawakami T; Nishitoba T; Hoshi S; Uchida E; Tanaka H
J Clin Pharmacol; 2007 Oct; 47(10):1311-9. PubMed ID: 17652181
[TBL] [Abstract][Full Text] [Related]
40. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
